115 related articles for article (PubMed ID: 24956254)
1. Pharmacogenomics of methadone maintenance treatment.
Somogyi AA; Barratt DT; Ali RL; Coller JK
Pharmacogenomics; 2014 May; 15(7):1007-27. PubMed ID: 24956254
[TBL] [Abstract][Full Text] [Related]
2. Impact of genetic polymorphisms in ABCB1, CYP2B6, OPRM1, ANKK1 and DRD2 genes on methadone therapy in Han Chinese patients.
Hung CC; Chiou MH; Huang BH; Hsieh YW; Hsieh TJ; Huang CL; Lane HY
Pharmacogenomics; 2011 Nov; 12(11):1525-33. PubMed ID: 21902500
[TBL] [Abstract][Full Text] [Related]
3. Methadone dose in heroin-dependent patients: role of clinical factors, comedications, genetic polymorphisms and enzyme activity.
Mouly S; Bloch V; Peoc'h K; Houze P; Labat L; Ksouda K; Simoneau G; Declèves X; Bergmann JF; Scherrmann JM; Laplanche JL; Lepine JP; Vorspan F
Br J Clin Pharmacol; 2015 Jun; 79(6):967-77. PubMed ID: 25556837
[TBL] [Abstract][Full Text] [Related]
4. Genetic polymorphisms in the opioid receptor mu1 gene are associated with changes in libido and insomnia in methadone maintenance patients.
Wang SC; Tsou HH; Chen CH; Chen YT; Ho IK; Hsiao CF; Chou SY; Lin YF; Fang KC; Huang CL; Su LW; Fang YC; Liu ML; Wu HY; Lin KM; Liu SC; Kuo HW; Chiang IC; Chen AC; Tian JN; Liu YL
Eur Neuropsychopharmacol; 2012 Oct; 22(10):695-703. PubMed ID: 22406240
[TBL] [Abstract][Full Text] [Related]
5. CYP2B6 and OPRM1 Receptor Polymorphisms at Methadone Clinics And Novel OPRM1 Haplotypes: A Cross-Sectional Study.
AlMeman AA; Ismail R; Perola M
Drug Metab Lett; 2016; 10(3):213-218. PubMed ID: 27515451
[TBL] [Abstract][Full Text] [Related]
6. Genome-Wide Pharmacogenomic Study on Methadone Maintenance Treatment Identifies SNP rs17180299 and Multiple Haplotypes on CYP2B6, SPON1, and GSG1L Associated with Plasma Concentrations of Methadone R- and S-enantiomers in Heroin-Dependent Patients.
Yang HC; Chu SK; Huang CL; Kuo HW; Wang SC; Liu SW; Ho IK; Liu YL
PLoS Genet; 2016 Mar; 12(3):e1005910. PubMed ID: 27010727
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetics of opiates in clinical practice: the visible tip of the iceberg.
Hajj A; Khabbaz L; Laplanche JL; Peoc'h K
Pharmacogenomics; 2013 Apr; 14(5):575-85. PubMed ID: 23556453
[TBL] [Abstract][Full Text] [Related]
8. Implications of OPRM1 and CYP2B6 variants on treatment outcomes in methadone-maintained patients in Ontario: Exploring sex differences.
Chawar C; Hillmer A; Lamri A; Kapczinski F; Thabane L; Pare G; Samaan Z
PLoS One; 2021; 16(12):e0261201. PubMed ID: 34910759
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenomics of methadone: a narrative review of the literature.
Packiasabapathy S; Aruldhas BW; Horn N; Overholser BR; Quinney SK; Renschler JS; Sadhasivam S
Pharmacogenomics; 2020 Aug; 21(12):871-887. PubMed ID: 32705966
[No Abstract] [Full Text] [Related]
10. ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals.
Coller JK; Barratt DT; Dahlen K; Loennechen MH; Somogyi AA
Clin Pharmacol Ther; 2006 Dec; 80(6):682-90. PubMed ID: 17178268
[TBL] [Abstract][Full Text] [Related]
11. [Methadone and levomethadone - dosage and side effects].
Schoofs N; Riemer T; Bald LK; Heinz A; Gallinat J; Bermpohl F; Gutwinski S
Psychiatr Prax; 2014 Mar; 41(2):82-7. PubMed ID: 24254424
[TBL] [Abstract][Full Text] [Related]
12. Impact of SNP-SNP interaction among ABCB1, ARRB2, DRD1 and OPRD1 on methadone dosage requirement in Han Chinese patients.
Luo R; Li X; Qin S; Luo Z; Luo X; Hu P; Liu Z; Feng X; Li X
Pharmacogenomics; 2017 Dec; 18(18):1659-1670. PubMed ID: 29173032
[TBL] [Abstract][Full Text] [Related]
13. [Association between DRD2 gene polymorphisms and the dosage used on methadone maintenance treatment program].
Duan LX; Li XL; Hu PW; Luo R; Luo X; Chen YY
Zhonghua Liu Xing Bing Xue Za Zhi; 2018 Feb; 39(2):194-198. PubMed ID: 29495204
[No Abstract] [Full Text] [Related]
14. Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action.
Lötsch J; Skarke C; Wieting J; Oertel BG; Schmidt H; Brockmöller J; Geisslinger G
Clin Pharmacol Ther; 2006 Jan; 79(1):72-89. PubMed ID: 16413243
[TBL] [Abstract][Full Text] [Related]
15. Role of Methadone in Induction and/or Exacerbation of Cluster Headache in Patients Treated for Opioid Addiction.
Diot C; Eiden C; Leglise Y; Donnadieu-Rigole H; Peyrière H
Therapie; 2015; 70(3):305-7. PubMed ID: 25487851
[TBL] [Abstract][Full Text] [Related]
16. OPRM1 genetic polymorphisms are associated with the plasma nicotine metabolite cotinine concentration in methadone maintenance patients: a cross sectional study.
Chen YT; Tsou HH; Kuo HW; Fang CP; Wang SC; Ho IK; Chang YS; Chen CH; Hsiao CF; Wu HY; Lin KM; Chen ACh; Tsai-Wu JJ; Liu YL
J Hum Genet; 2013 Feb; 58(2):84-90. PubMed ID: 23223006
[TBL] [Abstract][Full Text] [Related]
17. OPRM1 and CYP3A4 association with methadone dose in Iranian patients undergoing methadone maintenance therapy.
Akbari A; Kheradmand A; Sina M; Ahmadiani A; Asadi S
J Addict Dis; 2021; 39(3):357-362. PubMed ID: 33682628
[TBL] [Abstract][Full Text] [Related]
18. ABCB1 haplotype and OPRM1 118A > G genotype interaction in methadone maintenance treatment pharmacogenetics.
Barratt DT; Coller JK; Hallinan R; Byrne A; White JM; Foster DJ; Somogyi AA
Pharmgenomics Pers Med; 2012; 5():53-62. PubMed ID: 23226062
[TBL] [Abstract][Full Text] [Related]
19. Association of genetic variation in pharmacodynamic factors with methadone dose required for effective treatment of opioid addiction.
Levran O; Peles E; Randesi M; Shu X; Ott J; Shen PH; Adelson M; Kreek MJ
Pharmacogenomics; 2013 May; 14(7):755-68. PubMed ID: 23651024
[TBL] [Abstract][Full Text] [Related]
20. OPRM1 and CYP2B6 gene variants as risk factors in methadone-related deaths.
Bunten H; Liang WJ; Pounder DJ; Seneviratne C; Osselton D
Clin Pharmacol Ther; 2010 Sep; 88(3):383-9. PubMed ID: 20668445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
